Unjha Formulations FY26 Audited Results: Annual Net Profit Rises to ₹70.47 Lacs, Revenue at ₹1,574.87 Lacs

4 min read     Updated on 18 May 2026, 03:03 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Unjha Formulations Limited reported audited standalone financial results for the quarter and year ended 31 March 2026, with annual net profit rising to ₹70.47 lacs from ₹40.76 lacs in FY25 and total income from operations growing to ₹1,574.87 lacs. The Q4 FY26 quarter recorded a net loss of ₹74.28 lacs, while total assets expanded to ₹551.04 lacs and cash and cash equivalents surged to ₹164.48 lacs. The board also approved the appointment of M/s Ajay Parikh & Associates as Secretarial Auditor for FY 2025-26.

powered bylight_fuzz_icon
40640496

*this image is generated using AI for illustrative purposes only.

Unjha Formulations Limited's Board of Directors convened on 18 May 2026 and approved the audited standalone financial results for the quarter and year ended 31 March 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also submitted an Integrated Filing (Financial) under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated January 2, 2025. The board meeting commenced at 12.30 p.m. and concluded at 2.00 p.m. Statutory auditors Jain & Golechha, Chartered Accountants (FRN: 119637W), issued an unmodified audit opinion on the annual financial results.

Annual Financial Performance

For the full year ended 31 March 2026, Unjha Formulations recorded a meaningful improvement in both revenue and profitability compared to the previous year. Total income from operations rose to ₹1,574.87 lacs from ₹1,397.68 lacs in FY25, while net profit for the period grew to ₹70.47 lacs from ₹40.76 lacs. The following table summarises the key annual financial metrics (all figures in Rs. in Lacs):

Metric: FY26 (Audited) FY25 (Audited)
Net Sales/Income from Operations: ₹1,558.52 ₹1,386.21
Other Operating Income: ₹16.36 ₹11.47
Total Income from Operations (Net): ₹1,574.87 ₹1,397.68
Total Expenditure: ₹1,479.49 ₹1,345.32
Profit from Operations (before other income, finance cost & exceptional items): ₹95.38 ₹52.36
Net Profit for the Period: ₹70.47 ₹40.76
Total Comprehensive Income: ₹70.47 ₹40.76
Basic EPS (₹, not annualised): ₹1.57 ₹0.91
Diluted EPS (₹, not annualised): ₹1.57 ₹0.91

Quarterly Financial Performance

For the quarter ended 31 March 2026, the company reported total income from operations of ₹332.82 lacs, compared to ₹443.90 lacs in the preceding quarter ended 31 December 2025 and ₹243.90 lacs in the corresponding quarter of the previous year. The quarter recorded a net loss of ₹74.28 lacs, against a net profit of ₹23.97 lacs in Q3 FY26 and a net loss of ₹40.64 lacs in Q4 FY25. Key quarterly metrics are presented below (all figures in Rs. in Lacs):

Metric: Q4 FY26 (31.03.2026) Q3 FY26 (31.12.2025) Q4 FY25 (31.03.2025)
Total Income from Operations (Net): ₹332.82 ₹443.90 ₹243.90
Total Expenditure: ₹382.19 ₹419.93 ₹272.94
Profit/(Loss) from Operations: -₹49.37 ₹23.97 -₹29.04
Net Profit/(Loss) for the Period: -₹74.28 ₹23.97 -₹40.64
Basic EPS (₹, not annualised): -₹1.66 ₹0.53 -₹0.91
Diluted EPS (₹, not annualised): -₹1.66 ₹0.53 -₹0.91

Balance Sheet Highlights

As at 31 March 2026, the company's total assets stood at ₹551.04 lacs, up from ₹455.74 lacs as at 31 March 2025. Cash and cash equivalents increased significantly to ₹164.48 lacs from ₹64.38 lacs in the prior year. Equity share capital remained unchanged at ₹448.05 lacs. Key balance sheet figures are as follows (all figures in Rs. in Lacs):

Parameter: 31.03.2026 (Audited) 31.03.2025 (Audited)
Total Non-Current Assets: ₹129.84 ₹120.22
Total Current Assets: ₹421.19 ₹335.52
Total Assets: ₹551.04 ₹455.74
Equity Share Capital: ₹448.05 ₹448.05
Other Equity: -₹63.71 -₹134.17
Total Non-Current Liabilities: ₹0.00 ₹0.48
Total Current Liabilities: ₹166.70 ₹141.37
Total Equity and Liabilities: ₹551.04 ₹455.74

Cash Flow Summary

The company generated net cash from operating activities of ₹124.38 lacs for the year ended 31 March 2026, a marked improvement compared to a net cash outflow of ₹(4.49) lacs in the prior year. Net cash used in investing activities was ₹(23.49) lacs, primarily on account of purchase of property, plant and equipment worth ₹(23.49) lacs. Net cash used in financing activities stood at ₹(0.79) lacs. As a result, cash and cash equivalents at the end of the period rose to ₹164.48 lacs from ₹64.38 lacs at the beginning of the period.

Corporate Developments

At the same board meeting, the Board, on the recommendation of the Audit Committee, approved the appointment of M/s Ajay Parikh & Associates, Company Secretaries, Ahmedabad, as the Secretarial Auditor of the company to conduct the Secretarial Audit for FY 2025-26. The statutory auditors, Jain & Golechha, Chartered Accountants, issued an audit report with an unmodified opinion in respect of the annual audited standalone results for the year ended 31 March 2026, in accordance with SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27 May 2016. The company operates in a single business segment, and accordingly, the reported figures represent the performance of that segment.

Historical Stock Returns for Unjha Formulations

1 Day5 Days1 Month6 Months1 Year5 Years
+0.21%+1.47%-7.96%-24.87%-16.09%+100.21%

What specific operational or cost-side factors drove the sharp Q4 FY26 net loss of ₹74.28 lacs despite full-year profitability, and can management address these seasonality risks in FY27?

With other equity still deeply negative at -₹63.71 lacs, what is Unjha Formulations' timeline and strategy for fully eliminating accumulated losses and achieving a positive net worth?

Given the significant cash build-up to ₹164.48 lacs, how does the company plan to deploy this liquidity — through capacity expansion, product diversification, or potential acquisitions — to sustain revenue growth beyond FY26?

Unjha Formulations Limited Announces Board Meeting for FY26 Financial Results

1 min read     Updated on 22 Apr 2026, 04:53 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Unjha Formulations Limited has intimated the Bombay Stock Exchange about a scheduled board meeting to be held on 18 May 2026. The meeting, convened under Regulation 29(1)(a) of SEBI Listing Obligation and Disclosure Requirement Regulations, 2015, will consider the audited financial results for the quarter and year ended 31 March 2026 of the financial year 2024-25. Additionally, the board will discuss the appointment of a secretarial auditor for FY 2025-26. The meeting is scheduled to take place at 13.30 p.m. at the company's registered office in Sidhpur, Gujarat.

powered bylight_fuzz_icon
38402604

*this image is generated using AI for illustrative purposes only.

Unjha Formulations Limited has informed the Bombay Stock Exchange about an upcoming board meeting scheduled to be held on Monday, 18 May 2026. The meeting will be conducted at 13.30 p.m. at the company's registered office located at Khali Char Rasta, State Highway, Sidhpur - 384151. The intimation has been made in accordance with Regulation No. 29(1)(a) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Agenda for the Board Meeting

The board has outlined two key items on the agenda for discussion and consideration during the meeting:

  • To consider and take on record the Audited Financial Results of the company for the Quarter Ended as on 31.03.2026 and Year Ended as on 31.03.2026 of the Financial Year 2024-25
  • To appoint a Secretarial Auditor for FY 2025-26 of the Company

Meeting Details

Particulars Details
Date of Meeting 18 May 2026
Time 13.30 p.m.
Venue Registered Office, Khali Char Rasta, State Highway, Sidhpur - 384151
Regulation Reference Regulation 29(1)(a) of SEBI LODR Regulations, 2015

The communication, dated 21 April 2026, was addressed to the Manager (Listing) at the Bombay Stock Exchange Ltd. The intimation was signed by Krutiben M. Patel, Managing Director of the company, bearing DIN 01866427. Unjha Formulations Limited is registered with CIN NO. L99999GJ1994PLC022932 and GSTIN/UIN 24AAAACU1998G1Z7.

Historical Stock Returns for Unjha Formulations

1 Day5 Days1 Month6 Months1 Year5 Years
+0.21%+1.47%-7.96%-24.87%-16.09%+100.21%

What factors might influence Unjha Formulations' financial performance in FY 2025-26 given the current pharmaceutical market conditions?

How could the appointment of a new secretarial auditor impact the company's governance practices and compliance framework going forward?

What strategic initiatives might Unjha Formulations announce alongside their annual results to drive growth in FY 2026-27?

More News on Unjha Formulations

1 Year Returns:-16.09%